The CD47 inhibitors market is anticipated to experience substantial growth in the near future, driven by the anticipated launch of late-stage pipeline drugs ...

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...

Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Although not all bats carry rabies, the city's health department wants people to seek post-exposure prophylaxis if they were bitten, scratched, or had contact with a bat. Meanwhile, travelers from ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

RSV vaccine sales by GSK and Pfizer have dropped in the U.S. after regulators limited the eligible age group, affecting ...